The concerns I have read even on BPDCN data are that even though early data looks good, the side effects limit the number of cycles of treatment a given patient can receive. Don't follow closely so don't know how valid those concerns are.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.